The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- Overlapping of All-Case Surveys and EPPV Inefficient: Mr Uda of FPMAJ
April 7, 2015
- PMDA Reviewing Plavix for Risk of Acute Generalized Exanthematous Pustulosis
April 6, 2015
- Editor’s Pick: Five Healthcare News Headlines for March 23 - April 5
April 6, 2015
- Govt, Pharma Leaders to Hold Policy Dialogue on April 13
April 6, 2015
- Abe Pins Hopes of Innovation on AMED
April 6, 2015
- MHLW to Accept Applications for “Sakigake” Designation from May 8
April 6, 2015
- MHLW Orders Revision of Package Inserts for Cetuximab, Panitumumab
April 3, 2015
- MHLW Requires Municipalities to Compile Generic Promotion Plans for Welfare Recipients
April 3, 2015
- AMED Inaugurated with Diverse Talents as Unit Heads
April 2, 2015
- MHLW Notifies of New Criteria for Orphan Drug Designation
April 2, 2015
- MHLW Notifications Prod Generic Use under High-Cost Healthcare Benefit System
April 2, 2015
- PMDA Sets Up New Unit to Promote Medical Database Project
April 1, 2015
- LDP Legislators Discuss Legal Regulation of Clinical Research
April 1, 2015
- MHLW to Invite Candidate Products for “Sakigake” Designation System
March 31, 2015
- MHLW Reiterates Caution on Skin Disorders for Lamictal: Safety Bulletin
March 31, 2015
- Otani, Ex-Number 2 at MHLW, Tapped as Aide to Chief of AMED
March 30, 2015
- PMDA Launches Consultation Services for Academia-Led Trials
March 30, 2015
- MHLW OKs 32 Products Including Sovaldi, Lenvima
March 27, 2015
- Nonpartisan Group Launched to Push Biosimilar Use, Lawmaker-Sponsored Bill Eyed
March 27, 2015
- Govt OKs AMED’s 5-Year Plan Articulating Support for 200 Drug Seed Development Projects
March 26, 2015
ページ
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…